Advisors Management Group Inc. ADV Purchases 110 Shares of Johnson & Johnson (NYSE:JNJ)

Advisors Management Group Inc. ADV raised its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 29,106 shares of the company’s stock after acquiring an additional 110 shares during the period. Johnson & Johnson makes up approximately 1.0% of Advisors Management Group Inc. ADV’s investment portfolio, making the stock its 27th largest position. Advisors Management Group Inc. ADV’s holdings in Johnson & Johnson were worth $4,827,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in JNJ. WealthTrak Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $29,000. Conquis Financial LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $38,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 0.2%

Shares of NYSE:JNJ opened at $155.59 on Thursday. The company has a fifty day moving average of $153.63 and a 200-day moving average of $153.88. The company has a market capitalization of $374.36 billion, a PE ratio of 17.31, a price-to-earnings-growth ratio of 2.36 and a beta of 0.41. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were paid a $1.30 dividend. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.34%. Johnson & Johnson’s payout ratio is currently 57.84%.

Analyst Ratings Changes

A number of research firms have recently weighed in on JNJ. Sanford C. Bernstein reiterated a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Guggenheim restated a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Benchmark upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Thursday, April 24th. Wall Street Zen upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 21st. Finally, Bank of America lowered their price objective on shares of Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday, April 10th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.